A Trial to Evaluate the Effect of Low Dose Temozolomide (TMZ) for 2 Weeks on Brain Tumor O-6-Methylguanine-DNA Methyltransferase (MGMT) Activity in Patients With Gliomas.

Trial Profile

A Trial to Evaluate the Effect of Low Dose Temozolomide (TMZ) for 2 Weeks on Brain Tumor O-6-Methylguanine-DNA Methyltransferase (MGMT) Activity in Patients With Gliomas.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2012

At a glance

  • Drugs Temozolomide (Primary)
  • Indications Anaplastic astrocytoma; Astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
  • Focus Therapeutic Use
  • Sponsors Schering-Plough
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Jan 2012 Actual end date changed from Jan 2011 to Feb 2011 as reported by ClinicalTrials.gov.
    • 02 Feb 2011 Planned end date changed from 1 Mar 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top